Masimo Corporation (NASDAQ:MASI) recently announced that NuVision Management Healthcare Consulting Company is deploying a variety of Masimo technologies at its four pediatric care facilities in New Jersey and Florida.
More on the Deal
NuVision will be equipping Voorhees Pediatric, Weisman Children’s Rehabilitation Hospital, Plantation Kidz Korner and Clark Nursing and Rehabilitation Center will be equipped with Masimo SET, Root with Radical-7, NomoLine Capnography and Patient SafetyNet.
Notably, every patient at the locations would be having access to Masimo Root Patient Monitoring and Connectivity Hubs equipped with Radical-7 Pulse CO-Oximeters, allowing patients to be monitored using Masimo SET Measure-through Motion and Low Perfusion pulse oximetry.
Additionally, a variety of other rainbow SET parameters. NomoLine capnography, available as a MOC-9 expansion module for Root, will be used to support the management of children on ventilators.
Other Recent Developments
Masimo recently announced 510(k) clearance from the FDA for Radius PPG. This will prove beneficial for the company as Radius PPG utilizes the power of the clinically-proven Masimo SET technology that delivers accurate measurement while patients are on the move. This in itself is expected to be a significant breakthrough in patient monitoring.
Earlier this month, Masimo along with Mdoloris Medical Systems announced the CE marking of the Mdoloris Analgesia Nociception Index module for the Masimo Root Patient Monitoring and Connectivity Hub. (Read More: Masimo Gets CE Mark for ANI Module, Enhances Root Platform)
Price Performance
Banking on the above developments, shares of the Zacks Rank #2 (Buy) company have rallied 38.6% against the industry’s 4.2% decline. The current level also compares favorably with the S&P 500 index’s 3.1% rise.
Other Stocks that Warrant a Look
Other top-ranked stocks in the broader medical space are Cerner Corporation (NASDAQ:CERN) , Penumbra (NYSE:PEN) and Bruker Corporation (NASDAQ:BRKR) . While Cerner sports a Zacks Rank #1 (Strong Buy), the other two stocks carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cerner’s long-term earnings growth rate is expected to be 13.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Bruker’s long-term earnings growth rate is estimated at 11.7%.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Cerner Corporation (CERN): Free Stock Analysis Report
Bruker Corporation (BRKR): Free Stock Analysis Report
Penumbra, Inc. (PEN): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
Original post